News Release

A strategic vision for the future of Redox Medicine

"Exploring Emerging Trends, Biomarkers, and Therapeutic Possibilities" will be discussed and exposed in Paris during the annual meeting of the Redox Medicine Society on June 27-28.

Meeting Announcement

Mitochondria-Microbiota Task Force

Redox Medicine: Transforming Health Strategies and Aging Perspectives


The redox medicine field is set to transform numerous health prevention strategies, providing clear insights into the dual roles that antioxidants play in both promoting health and managing diseases. A strategic focus of this field is aging, both externally and internally. This encompasses not only the visible signs of aging but also the internal cellular and molecular processes that contribute to the aging phenotype and associated health challenges.

view more 

Credit: Redox Medicine Society (RMS).

The "Redox Medicine 2024" conference gathers leading experts to discuss the pivotal role of redox processes in medical science. Covering a wide range of topics, from drug development to the management of chronic diseases, the speakers explore into how redox science is integral to understanding disease pathology and crafting innovative treatments.

They examine the impact of oxidative stress and redox signaling in various conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders. This collection of talks highlights emerging therapeutic strategies, including the use of antioxidants, novel small molecule drugs, and the potential of artificial intelligence in advancing redox medicine.

The conference serves as a crucial platform for sharing cutting-edge research and fostering collaborations that aim to harness the power of redox processes to improve health outcomes.

1. Bruce Freeman (University of Pittsburgh, USA) explores the therapeutic potential of small molecule electrophiles derived from nitrogen oxides, emphasizing drug development based on redox chemistry.

2. Miria Ricchetti (Institut Pasteur, France) discusses the "Redox Interactome" in physiopathology, detailing how redox reactions influence disease mechanisms.

3. Martin O. Bergo (Karolinska Institutet, Sweden) presents findings on how antioxidants can enhance blood flow in tumors, offering new angles for cancer treatment.

4. Mario D. Cordero (Universidad Pablo de Olavide, Spain) investigates superinflammasome complexes in human diseases, highlighting the role of redox signaling.

5. Christel Marquette (Laboratoire Biosanté U1292 INSERM-CEA-UGA, France) addresses the regulation of reactive species by prokineticin antagonist in cerebral dementia.

6. Zaher El Beck (Karolinska Institutet and Uppsala University, Sweden) links epigenetic modulators to mitochondrial redox homeostasis and cardiac function, emphasizing sex-dependent differences.

7. Tamara Tomin (TU Wien, Austria) covers metabolic regulation by redox signaling in the heart, expanding understanding of cardiovascular health.

8. Laurent Chatre (ISTCT, CNRS, France) discusses the reactive species interactome, mitochondria, and gender differences in brain metabolism.

9. Roberta Rizzo (Università degli Studi di Ferrara, Italy) focuses on NADH as a redox sensor in aging-related disorders, offering insights into aging processes.

10. Andrew Cumpstey (University of Southampton, UK) examines redox implications of supplementary oxygen during major abdominal surgery.

11. Daniel Vaiman (DR1 INSERM, Institut Cochin, France) studies oxidative stress in hypertensive diseases of pregnancy, aiming to improve maternal health.

12. Carole Nicco (President of Redox Medicine Society) presents on biomarkers in redox medicine, pointing to diagnostic and therapeutic potentials.

13. Sayuri Miyamoto (University of São Paulo, Brazil) identifies oxidized lipids in neurodegenerative diseases, linking lipid oxidation to neurological decline.

14. Jumana Saleh (Sultan Qaboos University, Oman) explores HDL oxidative stress in post-COVID disease and its relation to disease severity.

15. Radia Tamarat (IRSN, France) connects redox processes with radiotherapy and biomarkers, providing a basis for refined cancer treatment protocols.

16. Jeffrey A. Johnson (University of Wisconsin, USA) discusses targeting the Keap1/Nrf2 pathway in chronic neurodegenerative diseases, offering a strategy for therapeutic intervention.

17. George M. Spyrou (The Cyprus Institute of Neurology & Genetics, Cyprus) focuses on drug repurposing for Alzheimer's disease and NRF2 modulation.

18. Duncan Emerton (Vice-President of Citeline, UK) talks about the pharmaceutical industry's search for redox-modulating therapeutics.

19. Antonio Vila-Coro (IQVIA, Spain) outlines the drug development process from preclinical to clinical stages.

20. Stéphane Mouchabac (CHU St Antoine DMU Neurosciences and Institut du Cerveau, Paris) examines the use of artificial intelligence in neuroinflammation and redox medicine.

21. Maxime Barat (Université Paris Cité, France) discusses the applications of artificial intelligence and algorithms in radiology and redox medicine.

These speakers highlight the pivotal role of redox processes in understanding and treating a wide range of health issues, from neurodegenerative diseases to cardiovascular health, emphasizing the importance of redox medicine in contemporary medical research and therapy development.

For more information about the conference program, speakers, and more, please visit the website:

For conference or media inquiries please contact:


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.